Pimecrolimus
- TRADE NAME: Elidel (Valeant)
- INDICATIONS: Second-line therapy for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis
- CLASS: Immunomodulator, Macrolactam
- HALF-LIFE: N/A
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Abatacept, Alcohol, Alefacept, Aprepitant, Azacitidine, Betamethasone, Cabazitaxel, Calcium channel blockers, Cimetidine, Conivaptan, CYP3A4 inhibitors, Darunavir, Delavirdine, Denileukin, Docetaxel, Efavirenz, Erythromycin, Fingolimod, Fluconazole, Gefitinib, Immunosuppressants, Indinavir, Itraconazole, Ketoconazole, Lapatinib, Leflunomide, Lenalidomide, Oxaliplatin, Pazopanib, Pemetrexed, Pralatrexate, Telithromycin, Temsirolimus, Triamcinolone, Voriconazole
PREGNANCY CATEGORY: C
LONG-TERM SAFETY OF TOPICAL CALCINEURIN INHIBITORS HAS NOT BEEN ESTABLISHED.
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
CARDIOVASCULAR.
LOCAL.
OCULAR.
RESPIRATORY.
OTHER.
Page last updated 08/01/2022
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
